BioSpace News Archive

Income from operations for the fourth quarter of 2017 was $66.4 million, compared with $37.7 million for the same period in 2016.

Adverum Biotechnologies today announced the pricing of an underwritten public offering of 8,888,900 shares of its common stock at a price to the public of $6.75 per share.

Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company’s website.

The patent, which expires on 11 October 2033, allows iX Biopharma to exclusively use and obtain protection for its WaferiX drug delivery technology in China.

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc. (NASDAQ:CASC) at a price of $10.00 per share net to the seller in cash, without interest, less any applicable withholding taxes (the “Offer”).

The gross proceeds to Sage Therapeutics from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $575.0 million.